Ascletis-B Repurchases 200,000 Shares on 13 Oct; Outstanding Buybacks Awaiting Cancellation Rise to 2.05 Million

Bulletin Express10-13

Ascletis Pharma Inc. (ASCLETIS-B) disclosed a share repurchase of 200,000 ordinary shares on 13 October 2026 via on-market transactions. The purchase was executed within a price range of HKD 6.53–6.85 per share, for a total consideration of HKD 1.34 million.

Including this latest transaction, Ascletis has now bought back 2.55 million shares under the general mandate approved on 29 June 2026, representing approximately 0.24 % of the company’s issued share capital (excluding treasury shares) at the date of the mandate. Of these, 2.05 million shares are still pending formal cancellation as of 13 October 2026.

Key capital metrics following the disclosure: • Issued shares (excluding treasury shares): 1.052 billion • Treasury shares on hand: 5.78 million • Total issued shares (including treasury): 1.06 billion

The company remains authorized to repurchase up to 106.14 million shares under its existing mandate. In line with Hong Kong Stock Exchange rules, Ascletis is subject to a moratorium on issuing new shares or disposing of treasury shares until 12 November 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment